TY - JOUR
T1 - 免疫不全患者におけるCOVID–19 疾病負担
AU - Kuroishi, Naho
AU - Kanazu, Shinichi
AU - Takazono, Takahiro
AU - Okamoto, Akinao
AU - Tomita, Akihiro
AU - Yamanaga, Shigeyoshi
AU - Kenmochi, Takashi
AU - Egawa, Hiroto
AU - Inoue, Kento
AU - Kanegane, Hirokazu
AU - Taniguchi, Toshibumi
AU - Oku, Kenji
AU - Kikuchi, Kan
AU - Yotsuyanagi, Hiroshi
N1 - Publisher Copyright:
© 2023 Life Science Publishing Co. Ltd. All rights reserved.
PY - 2023
Y1 - 2023
N2 - Immuno compromised patients with congenital or acquired immune function-related abnormalities and those with depressed immune function due to the effects of medication(s) for treating another disease(s) are at greater risk of severe COVID-19 or death after contracting COVID-19 than the general population. Therefore, measures for preventing COVID-19 are extremely important in immuno compromised patients. However, the antibody response after vaccination is lower in immuno compromised patients than that in the general population due to the nature of the disease, i.e., immune deficiency. In this paper, we discuss the immune state and the effectiveness of COVID-19 vaccines in patients with hematological malignancies, solid organ transplantation, primary immunodeficiency disease, human immunodeficiency virus, rheumatic disease, and renal disease. We also consider the importance of new infection-preventing measures in addition to vaccines.
AB - Immuno compromised patients with congenital or acquired immune function-related abnormalities and those with depressed immune function due to the effects of medication(s) for treating another disease(s) are at greater risk of severe COVID-19 or death after contracting COVID-19 than the general population. Therefore, measures for preventing COVID-19 are extremely important in immuno compromised patients. However, the antibody response after vaccination is lower in immuno compromised patients than that in the general population due to the nature of the disease, i.e., immune deficiency. In this paper, we discuss the immune state and the effectiveness of COVID-19 vaccines in patients with hematological malignancies, solid organ transplantation, primary immunodeficiency disease, human immunodeficiency virus, rheumatic disease, and renal disease. We also consider the importance of new infection-preventing measures in addition to vaccines.
UR - http://www.scopus.com/inward/record.url?scp=85185512739&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85185512739&partnerID=8YFLogxK
M3 - 学術論文
AN - SCOPUS:85185512739
SN - 0289-8020
VL - 44
SP - 881
EP - 897
JO - Therapeutic Research
JF - Therapeutic Research
IS - 12
ER -
